Chapter 18: Drugs for Heart Failure

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

What if I told you that the human body's natural instinct to save a failing heart is actually like the exact thing that ends up destroying it?

Yeah, I mean it is basically the ultimate biological tragedy.

The body's own survival mechanisms become its absolute worst enemy.

Right, and if you are listening to this right now, there's a very good chance you are a college student staring down the barrel of your first major pharmacology exam.

Probably with a dangerously large cup of coffee.

Oh, absolutely.

You've got your notes open and you're trying to make sense of this massive mountain of drug classes, receptor pathways, and cellular mechanisms.

Which can be totally overwhelming.

It really is.

Yeah.

Well, you are exactly who we made this deep dive for.

Today we are completely decoding chapter 18 from Lippincott Illustrated Review's Pharmacology Seventh Edition.

That's the chapter on drugs for heart failure.

And we are going to do it logically, step by step.

We're sticking strictly to the text, taking the exact sequence of information you need to know, and building a story out of it.

Yeah, no jumping around, skipping the complex stuff.

Because, honestly, pharmacology isn't just about memorizing a dry list of generic names.

No, not at all.

It is about understanding a deeply interconnected system.

If you understand the underlying physiology, I promise you, the drugs naturally explain themselves.

So let's start with the baseline.

What are we actually dealing with here?

What is heart failure?

Well, it's a complex progressive disorder.

Simply put, the heart just cannot pump enough blood to meet the body's needs.

And because that pump is failing, you see three cardinal symptoms.

Right.

Dyspnea, which is severe shortness of breath, profound fatigue, and massive fluid retention.

Because the heart either can't fill up with blood properly or it can't eject that blood effectively.

Exactly.

To really grasp this, think of the failing heart like a struggling engine in an old car.

It's losing power, it's sputtering.

Yeah.

And as we'll see, the body's attempt to fix this struggling engine is essentially just, you know, throwing a brick on the gas pedal.

Which is catastrophic.

But to understand why,

we first have to look under the hood at the baseline cellular mechanics of a single heartbeat.

Figure 18 .2 and 18 .3 in the text.

Right, the cardiac action potential.

Before we can even look at the drugs, we have to trace the electrical voltage of a single heart muscle cell, a myocyte, over time.

And that gives us a very distinct wave with five phases.

Let's the spark.

It's this incredibly fast electrical upstroke where sodium channels just fly open and sodium rapidly rushes into the cell.

Okay, got it.

Then we get a tiny dip, which is phase one, right?

Yeah, that's where those sodium channels snap shut and potassium starts leaking out.

But phase two, this is where the magic happens.

The plateau phase.

Phase two is basically the absolute key to this entire deep dive.

It really is.

During this plateau, voltage sensitive calcium channels open up.

Calcium gets pulled inside the cell, which perfectly balances the positive potassium ions that are still leaving.

So we hold that electrical charge for a second and then phase three hits.

Right, repolarization.

The calcium channels close, potassium just floods out, and the cell's electrical charge resets.

And finally, phase four is just a slow, gradual leak of sodium back in, which automatically creeps the cell toward the threshold for the next beat.

But wait, let's rewind to that phase two plateau for a second.

Because that influx of calcium is the most important concept to master here.

Oh, absolutely.

A small amount of calcium enters the cell from the outside.

And that tiny bit of calcium acts as a trigger.

It literally knocks on the door of the sarcoplasmic reticulum inside the cell, causing it to release a massive secondary flood of its own stored calcium.

And here is the cardinal rule of cardiac pharmacology.

Write this down.

The force of the heart's contraction is directly mathematically related to concentration of free unbound calcium inside that cell.

More free intracellular calcium equals a stronger squeeze, period.

And we call that an inotropic effect.

Precisely.

A positive inotrope increases intracellular calcium, giving you a harder, more powerful contraction.

Okay, so that is the normal healthy engine.

But what happens when that engine starts to fail and cardiac output drops?

Well, the body panics.

It looks at the drop in pressure and initiates four major compensatory mechanisms.

Figure 18 .4 lays out this vicious cycle.

Mechanism number one.

The sympathetic nervous system kicks in.

Right.

The body has baroreceptors, which are basically pressure sensors in the arteries.

When cardiac output drops, blood pressure drops.

These sensors sound the alarm.

The brain interprets this drop in pressure as a massive crisis, like you were physically bleeding out.

It doesn't realize the pump itself is broken.

Exactly.

So what does it do?

It floods the system with adrenaline and noradrenaline.

It stimulates the beta adrenergic receptors on the heart to increase the heart rate and the force of contraction.

And it constricts the blood vessels to push more blood back to the central organs.

So our failing, completely exhausted car engine is suddenly being redlined by adrenaline.

Which brings us to mechanism number two, the renin angiotensin aldosterone system, or the RAS pathway.

Yeah, as the heart fails, blood flow to the kidneys drops.

Now the kidneys are the body's ultimate fluid regulators.

When they sense low flow, they assume the body is dehydrated.

So they release an enzyme called renin.

And renin initiates this massive hormonal domino effect.

It ultimately creates angiotensin the second, which is one of the most potent vasoconstrictors in the human body.

It just clamps down all the blood vessels.

Right.

And then angiotensin the second triggers the release of aldosterone from the adrenal glands.

And aldosterone is bad news here because it forces the kidneys to hoard massive amounts of sodium.

And we know the rule, wherever sodium goes, water follows.

Exactly.

The result is the body retains huge volumes of fluid, blood volume spikes, forcing fluid out of the vessels and into the tissue.

Causing that classic edema, the swelling in the legs and the lungs that we always see in heart failure patients.

And to make matters worse, angiotensin the second and aldosterone are directly toxic to the heart muscle.

They cause inflammation, fibrosis, and abnormal cellular growth.

Which leads right into mechanism number three, myocardial hypertrophy.

The heart muscle physically changes shape.

Yeah, it stretches and thickens to try and handle all this extra fluid and pressure.

And clinically, the text shows us this manifests in two distinct ways.

Right.

If the ventricle over stretches, becomes thin and floppy and just loses its ability to pump effectively, we call that HFREF, heart failure with reduced ejection fraction.

So that's a systolic failure.

The engine just can't squeeze.

On the flip side, if the ventricular wall thickens, becomes incredibly stiff and hypertrophies, it can't relax enough to actually fill up with blood in the first place.

And that is

HFPEF, heart failure with preserved ejection fraction.

Right.

It's a diastolic filling problem.

You essentially have a stiff leather pouch instead of a flexible balloon.

Though to be fair, patients often have a mix of both.

Okay.

Finally, we have the fourth compensatory mechanism, natriuretic peptides.

When the heart is stretched to its absolute limit, the muscle cells release these peptides.

And these are actually the good guys, right?

Like this is the one purely beneficial response.

They are.

These peptides try to promote vasodilation and natriuresis, which is the excretion of that excess sodium into the urine.

They are desperately trying to relieve the pressure.

But it's a losing battle.

Oh, totally.

The sheer overwhelming force of the sympathetic nervous system and the RAAS pathway completely overpowers the beneficial peptides.

Okay.

Let's unpack this.

Look at it logically.

The pump is exhausted.

The muscle is failing.

So the body responds by injecting pure adrenaline, clamping all the blood vessels shut, and overloading the system with extra fluid volume.

It is literally throwing a brick on the gas pedal of a car that already has a blown gasket.

That is exactly why heart failure is progressive terminal disease if left untreated.

The compensation causes the destruction.

Which brings us to section two, the actual pharmacology, breaking the cycle.

Since the body's RAAS system is acting like that brick on the gas pedal, the very first step in pharmacological intervention is to pry it off.

We have to shut down RAAS.

Enter the ACE inhibitors.

This is figure 18 .5 in your book.

These are the famous drugs.

Keptapril, analapril, lisinopril.

Let's trace the mechanism.

ACE inhibitors block the angiotensin -converting enzyme.

And without this enzyme, the body cannot convert inactive angiotensin I into the highly toxic vasoconstricting angiotensin II.

The downstream effects of this are profound.

Because you don't have angiotensin II clancing the vessels,

venous tone drops.

Right, which reduces preload or the volume returning to the heart.

And vascular resistance also drops, which reduces afterload, the pressure the heart has to push against.

Cardiac output naturally increases because the engine isn't fighting so much resistance anymore.

And most importantly, ACE inhibitors significantly improve patient survival.

They stop that toxic cardiac remodeling in its tracks.

But there is a secondary pathway here that is incredibly important for exams.

The ACE enzyme isn't just responsible for making angiotensin II.

No, it is also responsible for breaking down a substance called bradykinin.

Wait, bradykinin causes vasodilation, right?

So if we block the enzyme that breaks it down, bradykinin levels rise and we get even more vasodilation.

That sounds like a good thing.

Well, it is a good thing for blood pressure, but it comes with a notorious clinical catch.

Oh, the cough.

Yes.

Elevated bradykinin causes severe irritation in the respiratory tract.

It results in a relentless dry hacking cough in a significant percentage of patients.

And in rare cases, it can cause angioedema, which is a rapid, life -threatening swelling of the lips, tongue, and throat.

That is a classic exam question.

Definitely highlight that.

Speaking of exam details, there are some vital pharmacokinetics with ACE inhibitors you need to know.

Yeah, almost all of them are pro -drugs, meaning they have to be processed by the liver to become active.

Except for captopril and the injectable form of enolapyril, which is called enolapyrot.

Those are active right out of the right.

Also, phosphopril is unique because it's cleared through both the kidneys and the liver, whereas the others rely heavily on just renal elimination.

And because of that renal clearance, you have to monitor these patients carefully.

You watch their serum creatinine levels to make sure the kidneys aren't failing.

You also absolutely must monitor for hyperkalemia or dangerously high potassium, because blocking aldosterone means the body holds onto potassium instead of excreting it.

And finally, a major contraindication.

ACE inhibitors are strictly teratogenic.

They cause severe fetal malformations and cannot be used during pregnancy.

Good catch.

So let's say our patient develops that horrible, dry bradykin and cough.

They can't sleep.

They are miserable.

We have to take them off the ACE inhibitor.

What's the substitute?

We move to the ARBs, the angiotensin receptor blockers.

These are the dashed sartans, like losartan or vellsartan.

Right.

ARBs are competitive antagonists of the angiotensin II type 1 receptor.

So instead of stopping the production of angiotensin II, they just block the receptor it tries to bind to.

And here's the genius of it.

Because they don't mess with the ACE enzyme itself, they don't stop the breakdown of bradykinin.

Ah, so bradykinin levels stay normal.

Exactly.

You get all the life -saving benefits of reducing preload and afterload, but without the cough.

They are the standard go -to substitute.

Next up in dismantling the RAAS pathway are the aldosterone antagonists.

Spironolactone and epiluron.

We know from the pathology earlier that aldosterone is the hormone forcing the body to hoard salt and water.

And it directly causes the heart muscle to hypertrophy.

Right.

So these drugs block the mineralocorticoid receptor to stop all of that.

But spironolactone has a very weird, memorable quirk.

It really does.

Spironolactone doesn't just block aldosterone.

It also has a strange affinity for androgen and progesterone receptors.

Yeah, because it crosses over into other endocrine pathways, it can cause

gancomastia, which is the development of enlarged breast tissue in male patients.

And dysmenorrhea or irregular menstrual cycles in female patients.

Epiluronone is much more selective and doesn't usually cause these issues, but you know,

it's more expensive.

True.

Wrapping up the fluid volume discussion, we have to talk about diuretics, specifically loop diuretics like furosemide.

But I want to clarify a massive distinction here for the listeners.

Go for it.

So ACE inhibitors, ARBs, and aldosterone antagonists actually fix the underlying hormonal destruction of the heart.

But diuretics, they were just treating the symptoms right.

That is a critical point.

Yes, diuretics are incredibly effective at reducing plasma volume.

They force the kidneys to excrete water, which rapidly relieves the severe symptoms of volume overload.

The swelling in the legs goes down, the fluid clears from the lungs, the patient can breathe easily again.

They dramatically improve the quality of life.

But, and this is a huge, but they do not improve long -term survival in heart failure.

They don't stop the disease progression.

Not at all.

All right.

So moving to section three, we've pried the RAAS brick off the gas pedal and drain the excess fluid.

Now we have to deal with the sympathetic nervous system, which is still constantly bombarding the heart with adrenaline.

This brings us to beta blockers, drugs like

Wait, hold on.

This is where the logic seems to totally fall apart.

You just told me earlier that calcium and strong contractions are what the heart desperately needs to pump blood.

Beta blockers slow the heart down.

They have a negative inotropic effect.

They literally weaken the contraction.

Right.

Why on earth would I give a cardiac depressant to a pump that is already failing?

It sounds completely contradictory, doesn't it?

In fact, for decades, the medical community thought beta blockers were strictly contraindicated in heart failure for that exact reason.

Yeah.

Why depress a failing pump?

But long -term clinical trials revealed a stunning truth.

The constant barrage of adrenaline and norepinephrine from the sympathetic nervous system is highly toxic to the heart muscle over time.

Oh, so it causes rapid cell death, hypertrophy, and devastating structural remodeling.

Exactly.

So by giving a beta blocker, you are essentially installing a speed governor on the You are sacrificing a tiny bit of short -term pumping power in order to stop the engine from melting itself down over the next year.

That is exactly what you are doing.

By slowing the heart rate, reducing the force of contraction, and indirectly inhibiting renin release, beta blockers prevent that deleterious remodeling.

They actually reverse it over time.

The long -term survival benefits are massive.

However, because they do initially depress cardiac function, they can actually make a patient's symptoms slightly worse for the

The clinical rule is start low and go slow.

Precisely.

You initiate beta blockers at microscopic doses and very gradually titrate them up as the patient's heart adjusts to the governor.

You have to ease the heart into the blockade.

Next, we have a relatively novel, brilliant therapy, the ARNI.

That stands for angiotensin receptor nepolysin inhibitor.

Right.

The drug combination is secubitral and valsartan.

Figure 18 .6 outlines this.

Let me see if I can piece this mechanism together based on what we've discussed so far.

We have those good nitritic peptides that the stretched heart releases to cause vasodilation.

Yes.

But the body has an enzyme called nepolysin that constantly sweeps through and destroys those good peptides.

Sacubitral is a nepolysin inhibitor.

Exactly.

So it acts like a bodyguard.

It takes out nepolysin, allowing the good peptides to stick around, accumulate, and protect the heart.

That is exactly how it works.

You are amplifying the body's only positive compensatory mechanism.

But to make this work, you have to simultaneously block the RAAS system.

Which is why sacubitral is physically combined in a single pill with valsartan, which is an ARB.

Right.

But here's the burning pharmacology question.

Why pair it with an ARB?

Why not pair it with an ACE inhibitor?

They both block RAAS.

It all comes back to our old friend bradykinin.

Nepolysin, the enzyme we are blocking with sacubitral, is also responsible for breaking down bradykinin.

Oh.

So if you inhibit nepolysin, bradykin levels naturally rise.

Yes.

And if you simultaneously use an ACE inhibitor, which also stops the breakdown of bradykinin.

You are hitting the system from two sides.

Bradykin levels would absolutely skyrocket.

And that combined effect causes a massive, unacceptable risk of fatal angioedema.

The swelling in the airway would be catastrophic.

Wow.

So therefore, sacubitral is strictly paired with an ARB, which doesn't affect bradykinin.

Exactly.

And in clinical practice, if you are transitioning a patient from an ACE inhibitor to an ARNI, you cannot just swap them on Tuesday.

Right.

The ACE inhibitor must be completely stopped for at least 36 hours before they take their first dose of the ARNI.

That 36 hour washout period is a guaranteed test question.

Highlight that.

Definitely.

Moving on, the last drug in this chronic management section is avabradine, figure 18 .7.

This is an HCN channel blocker.

Right.

This is a highly specific drug.

It selectively inhibits the hyperpolarization activated cyclic nucleotide gated channel.

That is a mouthful.

It is.

This particular channel is responsible for what electrophysiologists call the IF current, or the funny current, located directly in the sinoatrial node, the SA node, which is the heart's natural pacemaker.

So by slowing down this funny current, avabradine slows the firing of the pacemaker, which drops the overall heart rate.

Right.

But unlike beta blockers, it does this without reducing the force of contraction and without dropping blood pressure.

It just buys the ventricle more time to rest and fill with blood between beats.

Exactly.

It's used for patients who are already maxed out on beta blockers, but still have a resting heart rate over 70 beats per minute.

But because it targets these very specific hyperpolarization channels, it has a fascinating adverse effect.

It does.

It accidentally inhibits similar channels located in the retina of the eye.

So patients experience what's called luminous phenomena.

They describe sudden enhanced brightness or halos in their vision, especially when moving from a dark room to a bright one.

Yeah.

It is usually temporary, but it is a very unique side effect to watch out for.

Okay.

So into section four, we've built an incredible chronic long -term regimen.

We've blocked RAAS, we've governed the adrenaline, we've managed the fluid.

But what happens if the patient is still struggling or their heart failure is so advanced, they end up admitted to the hospital in an acute crisis.

That leads us to the short -term fixes, vasodilators and positive inotropes.

For vasodilators, the pharmacology highlights a specific fixed dose combination pill containing

hydrolazine, which is a direct arterial dilator,

and isosorbidonitrate, which is a venous dilator.

Together, they drop both preload and afterload.

Right.

And clinically, this specific combination has been proven to significantly improve symptoms and survival, specifically in self -identified black patients with HFREF who are already on standard therapy.

Though a quick warning for the exam,

hydrolazine is famous for causing a drug -induced lupus -like syndrome.

Oh, yeah.

So you have to monitor for joint pain and rashes.

Now we reach the ubilifters, the positive inotropic drugs.

The ones that increase the force of contraction.

Yes.

And I have to preface this with a grim clinical reality.

Inotropic drugs force intracellular calcium levels up to artificially increase the force of the heart's contraction.

Which absolutely improves cardiac output.

It does.

It clears fluid and the patient will feel dramatically better almost immediately.

But earlier we established that forcing the failing heart to work harder causes long -term destruction.

Exactly.

You are bypassing the engine's safety valves and injecting pure nitrous oxide into a failing motor.

You get a massive burst of speed and power, but you are actively accelerating the destruction of the engine.

All positive inotropes that increase intracellular calcium are associated with reduced long -term survival.

They basically trade tomorrow for today.

Because of this, they are mostly reserved for short -term inpatient use in severe crises.

And the granddaddy of all inotropes is digoxin.

It's a digitalis glycoside originally sourced from the beautiful but deadly foxglove plant.

Figures 18 .8 and 18 .9 map this out.

The cellular mechanism of digoxin is just a masterpiece of complex pharmacology.

Let's take this slow.

At the cellular membrane, digoxin directly binds to and inhibits a tiny transport machine called the sodium potassium ATPase pump.

Okay, under normal conditions, this pump uses energy to actively push sodium out of the cell and pull potassium in.

Right.

So if digoxin blocks this pump, the sodium that naturally leaks into the cell has nowhere to go.

Sodium begins to aggressively build up inside the heart muscle cell.

And because the internal sodium concentration gets so unusually high, it ruins the delicate concentration gradient needed for a completely different machine.

Which is the sodium calcium exchanger.

Exactly.

This is the brilliant part.

The exchanger usually uses the natural inward flow of sodium as the energy to shove calcium out of the cell.

Oh, but since the inside of the cell is now absolutely packed with sodium thanks to digoxin,

no new sodium wants to flow in.

The exchanger stalls out.

It stops working.

Which means the calcium gets trapped inside the cell.

It builds up and builds up.

And as we established in our very first rule, more intracellular free calcium means a massive, hypo -powerful contraction.

That is wild.

So digoxin pushes a decompensated, failing heart completely back toward a normal cardiac output curve.

It does.

It also enhances vagal tone, which happens to drop the heart rate, making it useful for certain arrhythmias too.

But the therapeutic window for digoxin is terrifyingly narrow.

It is one of the narrowest in all of pharmacology.

The dose that helps the patient is uncomfortably close to the dose that kills them.

Toxicity starts with vague symptoms, right?

Anorexia, nausea, vomiting.

Yeah.

Then neurological signs hit, like blurred vision or a classic yellowish tint to their sight.

And because digoxin alters the baseline resting electrical potential of the cell,

the heart becomes highly unstable.

Leading to severe, often fatal arrhythmias.

And we have to talk about potassium's role here because it is the ultimate trap for students.

Okay, let's hear it.

Digoxin actually competes with potassium to bind to that initial sodium -potassium pump.

Okay.

If a patient has normal potassium levels, the potassium fights back, keeping the digoxin somewhat in check.

But if a patient is hypokalemic...

Meaning their blood potassium is abnormally low.

Right.

There is no competition.

Digoxin binds relentlessly.

And why might a heart failure patient have low potassium?

Yeah.

Because they are taking loop diuretics like furosemide, which literally wastes potassium in the urine.

Exactly.

The loop diuretic causes hypokalemia.

The hypokalemia allows digoxin to bind relentlessly.

And the patient goes into fatal toxicity.

Wow.

So you have to monitor their electrolyte labs obsessively.

Obsessively.

Other short -term inpatient inotropes include beta agonists like dobutamine and dopamine and phosphodiesterase inhibitors like milrinone.

Figure 18 .10 shows both of these classes ultimately manipulate a messenger inside the cell called cyclic AMP.

Right.

Beta agonists stimulate the production of cyclic AMP.

Milrinone stops the breakdown of cyclic AMP.

In both cases, the cyclic AMP levels skyrocket.

This activates protein kinases that physically phosphorylate the calcium channels, locking them in the open position.

Calcium floods the cell, and the heart is forced into a violent, powerful contraction.

Again, these are IV only, used strictly in the ICU.

And finally, if IV diuretics are completely failing to clear fluid in a hospitalized patient, we have common B -type natriuretic peptide or nacerotide.

It is essentially an IV infusion of the body's natural beneficial peptides we discussed at the very beginning.

Right.

It stimulates heavy diuresis and vasodilation to just take the pressure off.

So Section 5, we have an entire pharmacy of highly complex options.

Diuretics, ACE inhibitors, beta blockers, ARNIs, inotropes.

How does a clinician logically organize this into a coherent treatment plan?

Figure 18 .11 gives us the treatment staircase.

It organizes therapy sequentially, from the least severe to the most severe stages of heart failure.

Think of it like building a protective fortress around the failing heart.

You layer your defenses one by one, ensuring the foundation is stable, rather than trying to fix it all with one magic bullet.

Let's walk the stairs.

Step one of the staircase is acute stabilization.

Right.

You use loop diuretics to aggressively manage the volume overload.

Get the fluid out of the lungs so the patient can breathe.

Step two is the foundation of the fortress.

Once stabilized, all newly diagnosed HFREF patients should be started on low doses of an ACE inhibitor or an ARB and a beta blocker.

You build that neurohormonal blockade immediately to stop the remodeling.

Step three.

If they are still showing symptoms despite optimal doses of those foundation drugs, you add another layer.

You introduce an aldosterone antagonist, like spironolactone, to further block RAAS, or perhaps the fixed -dose hydrolizine and isosorb identity.

Step four.

If they remain symptomatic, despite an optimal ACE inhibitor or ARB, you tear out that part of the foundation and upgrade it.

You swap the ACE inhibitor for the ARNI, the sacubitral -vulsartan combination, remembering that 36 -hour wash -up period.

And finally, step five.

At the very top of the stairs,

the absolute last resorts for chronic management are degoxin and iverdine.

Remember, these do not improve survival.

They are added purely for symptomatic benefit in patients who are already on optimized standard therapy but still severely struggling.

It is an incredibly elegant logical progression.

Start by relieving acute stress,

aggressively block the toxic biological compensation, and finally manage the residual symptoms.

If you can visualize that staircase and understand the cellular mechanics of each step, the pharmacology stops being a memorization game.

It becomes a sequence of deeply rational interventions.

Well, if you are that student listening right now, take a deep breath.

You have officially mastered this topic.

You really have.

You now understand how foundational cellular physiology dictates exact drug targets.

You know why an ACE inhibitor causes a cough?

Why beta blockers went from being banned to being mandatory?

And why degoxin toxicity is a deadly trap if potassium drops?

You know the why.

And the why is what gets you the grade.

But I want to leave you with a final provocative thought to mull over.

Based directly on the paradox of those inotropic drugs.

Okay, let's hear it.

If IV drugs like dobutamine and milrinone dramatically improve how the heart functions in the moment, making the cardiac output numbers on the monitor look fantastic, clearing the fluid, and making the patient feel momentarily stronger.

But the pharmacology approves they actively reduce the patient's overall survival.

It forces us to ask a profound question.

In medicine, are we treating the mechanical numbers on the monitor or are we treating the lifespan of the human being?

Wow.

You have to decide if your goal is just making the engine rev loud and proud today or if you're willing to slow it down to keep the car on the road for as long as possible.

That is the ultimate tension at the heart of heart failure management.

It really is.

Thank you so much from all of us at the Last Minute Lecture Team for tuning into this deep dive.

Keep those notes open.

Trust the physiology and good luck on your exam.